Is 5-MAPB Legal in Connecticut? (2026)

Instrument

statute

Source

https://eregulations.ct.gov/eRegsPortal/Search/RCSADisplay/21a-243-7

Retrieved

2026-06-19

Fingerprint

b1eb51cbe6059976

**Scheduling gap — § 21a-243-7(c):** the only tryptamines listed are alpha-ethyltryptamine, 5-MeO-DiPT, bufotenine/mappine, DET, DMT, … psilocybin, psilocyn; each is named individually and the sweep reaches only "their salts, isomers and salts of isomers." No "4-hydroxytryptamine" class, no general tryptamine catch-all. 4-HO-MET is not named and (as a homolog, not isomer) is not captured.
— Conn. Agencies Regs. § 21a-243-7(c) (amended, Tracking No. PR2025-018, posted 9/18/2025), official CT eRegulations: https://eregulations.ct.gov/eRegsPortal/Search/RCSADisplay/21a-243-7
**Definitional category, but NOT an independent schedule — Conn. Gen. Stat. § 21a-240(23):** "'Hallucinogenic substances' … Exemplary of such drugs are mescaline, peyote, psilocyn and d-lysergic acid diethylamide, which are controlled substances under this chapter unless modified." A substance is a "controlled substance" only if listed in Schedules I–V of the regulations (§ 21a-240(9)) — so this definition does **not** independently schedule 4-HO-MET.
— Conn. Gen. Stat. § 21a-240(23), (9); via labeled Justia mirror (2024), full section read: https://law.justia.com/codes/connecticut/title-21a/chapter-420b/section-21a-240/

Instrument

Regs. Conn. State Agencies 21a-243-7 (Schedule I), as amended by DCP regulation PR2025-018 (posted 9/18/2025; Regulation Review Committee file 2026REG2026-003)

Source

https://www.cga.ct.gov/2026/rrdata/pr/2026REG2026-003-RC.PDF

Retrieved

2026-10-08

Fingerprint

483048084506f8ec

Sec. 21a-243-7. Controlled substances in schedule I The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in schedule I: (a) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetylalpha-methylfentanyl; (2) Acetylmethadol; (3) Allylprodine; (4) Alphacetylmethadol (except Levo-alphacetylmethadol or LAAM); (5) Alphameprodine; (6) Alphamethadol; (7) Alpha-methylfentanyl; (8) Alphamethylthiofentanyl; (9) Benzethidine; (10) Betacetylmethadol; (11) Beta-hydroxy-fentanyl; (12) Beta-hydroxy-3-methylfentanyl; (13) Betameprodine; (14) Betamethadol; (15) Betaprodine; (16) Clonitazene; (17) Dextromoramide; (18) Diampromide; (19) Diethylthiambutene; (20) Difenoxin; (21) Dimenoxadol; Regulation - Page 1 of 7 Connecticut eRegulations System ,  Tracking Number PR2025-018 ,  Posted 9/18/2025 (22) Dimepheptanol; (23) Dimethylthiambutene; (24) Dioxaphetyl Butyrate; (25) Dipipanone; (26) Ethylmethylthiambutene; (27) Etonitazene; (28) Etoxeridine; (29) Furethidine; (30) Hydroxypethidine; (31) Ketobemidone; (32) Levomoramide; (33) Levophenacylmorphan; (34) 3-methylfentanyl; (35) 3-methylthiofentanyl; (36) Morpheridine; (37) Noracymethadol; (38) Norlevorphanol; (39) Normethadone; (40) Norpipanone; (41) Para-fluorofentanyl; (42) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); (43) Phenadoxone; (44) Phenampromide; (45) Phenomorphan; (46) Phenoperidine; (47) Piritramide; (48) Proheptazine; (49) Properidine; (50) Propiram; (51) Racemoramide; (52) Thiofentanyl; (53) Tilidine; (54) Trimeperidine. (b) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] of the following opium derivatives, their salts, isomers and salts of isomers, unless specifically excepted whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation: (1) Acetorphine; Regulation - Page 2 of 7 Connecticut eRegulations System ,  Tracking Number PR2025-018 ,  Posted 9/18/2025 (2) Acetyldihydrocodeine; (3) Benzylmorphine; (4) Codeine methylbromide; (5) Codeine-N-oxide; (6) Cyprenorphine; (7) Desomorphine; (8) Dihydromorphine; (9) Drotebanol; (10) Etorphine, except hydrochloride salts; (11) Heroin; (12) Hydromorphinol; (13) Methyldesorphine; (14) Methyldihydromorphine; (15) Morphine methylbromide; (16) Morphine methylsulfonate; (17) Morphine-N-oxide; (18) Myrophine; (19) Nicocodeine; (20) Nicomorphine; (21) Normorphine; (22) Pholcodine; (23) Thebacon. (c) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] material, compound, mixture or preparation which contains their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Alpha-ethyltryptamine; (2) 4-bromo-2,5-dimethoxyamphetamine; or 4-bromo-2,5-DMA; (3) 2,5-dimethoxyamphetamine; or 2,5-DMA; (4) 2,5-Dimethoxy-4-ethylamphetamone or DOET; (5) 3,4-M ethylenedioxy-N-ethylamphetamine; (6) 1-methyl-4-phenyl-4-propionoxypiperidine; or MPPP; (7) 3,4-methylenedioxymethamphetamine; or MDMA; (8) 2,5-dimethoxy-4-(n)-propylthiopenenthylamine (2C-T-7); (9) 4-methoxyamphetamine; or PMA; (10) 5-methoxy-3,4-methylenedioxy-amphetamine; (11) 5-Methoxy-nn-Diisopropyltryptamine(5-methoxy-dipt); (12) 4-methyl-2,5-dimethoxyamphetamine; or DOM; or STP Regulation - Page 3 of 7 Connecticut eRegulations System ,  Tracking Number PR2025-018 ,  Posted 9/18/2025 (13) 3,4-methylenedioxy amphetamine; or MDA; (14) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha- methyl- 3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA; (15) 3,4,5-trimethoxy amphetamine; (16) benzylpiperazine or BZP; (17) Bufotenine or Mappine; (18) Alphaethyltryptamine; (19) Diethyltryptamine or DET; (20) Dimethyltryptamine or DMT; (21) Ibogaine; (22) Lysergic acid diethylamide; (23) MDVP (3,4-methylenedioxypyrovalerone); (24) 3,4-methylenedioxy-N-methycathione (methylone) (25) Mephedrone (4-methylmethcathinone); (26) Mescaline; (27) Parahexyl or Synhexyl; (28) Peyote, meaning all parts of the plants; (29) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine; or PEPAP; (30) N-ethyl-3-piperidyl benzilate; (31) N-methyl-3-piperidyl benzilate; (32) Psilocybin; (33) Psilocyn; (34) Tetrahydrocannabinols except Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product; (35) Salvia divinorum; (36) Salvinorin A; (37) Ethylamine analog of phencyclidine, Cyclohexamine or PCE; (38) 4-Bromo-2,5-dimethoxyphenethylamine; (39) Pyrrolidine analog of phencyclidine, PCP or PHP; (40) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine; (41) Thiophene analog of phencyclidine, TPCP or TCP; (42) Tiletamine or 2-(ethylamino)-2-(2-thienyl)-cyclohexanone; (43) Trifluoromethylphenylpiperazine or TFMPP. (44) 7-hydroxymitragynine; (45) Bromazolam; (46) Flubromazolam; (47) Mitragyna speciosa (kratom), including its leaves, stem and any extracts; (48) Nitazenes, including, but not limited to, isotonitazene; (49) Tianeptine; and Regulation - Page 4 of 7 Connecticut eRegulations System ,  Tracking Number PR2025-018 ,  Posted 9/18/2025 (50) Phenibut. (d) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any [Any] material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, their salts, isomers and salts of isomers unless specifically excepted, wherever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation: (1) Gamma-hydroxy butyric acid, except if contained in a drug product for which an application has been approved under section 505 of the Food, Drug and Cosmetic Act; (2) Gamma-butyrolactone; (3) Mecloqualone; (4) Methaqualone; or (5) Zolazepam. (e) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: (1) Aminorex; (2) N-benzylpiperazine (some other names: BZP; 1-benzylpiperazine); (3) 4-Methylaminorex; (4) Cathinone; (5) Fenethylline; (6) Methcathinone; (7) N-ethylamphetamine; (8) N,N-Dimethylamphetamine. (f) Unless specifically excepted or unless listed in another schedule in the Connecticut General Statutes, or the regulations promulgated thereunder, or by the Food and Drug Administration, any material, compound, mixture or preparation which contains any quantity of a substance having a psychotropic response primarily by agonist activity at cannabinoid-specific receptors affecting the central nervous system. Specific compounds include, but are not limited to: (1) 1-pentyl-3-(1-naphthoyl)indole (JWH-018); (2) 1-butyl-3-(1-naphthoyl)indole (JWH-073); (3) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); (4) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497); (5) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabi-cyclohexanol CP- 47,497 C8 homologue). (g) Any schedule I controlled substance, used for a medical purpose under the supervision of a practitioner, that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designation for state purposes as that designated under the federal Controlled Substances Act, unless otherwise Regulation - Page 5 of 7 Connecticut eRegulations System ,  Tracking Number PR2025-018 ,  Posted 9/18/2025 specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the Connecticut General Statutes. Regulation - Page 6 of 7 Connecticut eRegulations System ,  Tracking Number PR2025-018 ,  Posted 9/18/2025 Statement of Purpose The purpose of this regulation is to designate new substances to the controlled substance list as required by Public Act 25-101, Section 4. This new law requires the Commissioner of Consumer Protection to designate the substances added to subsection (i) of that section as controlled substances and classify each such substance in the appropriate schedule. Since such substances currently have no medical use, pursuant to the Federal Drug Administration (FDA), and may not be prescribed or dispensed by a medical professional, the Department of Consumer Protection proposes this regulation to place the substances in schedule 1. However, if any of the substances are rescheduled by the FDA, this regulation contains an existing provision in subsection (g) to adopt the schedule determined by the FDA. Regulation - Page 7 of 7